Received Feb 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 42Y93 | IM / RL |
| HIBV | HIB (ACTHIB) | SANOFI PASTEUR | 2 | UK0422A | IM / LL |
| PNC20 | PNEUMO (PREVNAR20) | PFIZER\WYETH | 2 | HH590 | IM / LL |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | 2 | 2032353 | PO / MO |
Patient received 1 dose of DTAP-IVP Kinrix which is designated for ages 4-6 and he is 4 months old. The error was not known until 01/24/25 when I spoke with the physician when it did not appear on patient's medical record, (technical issues on the facilitie's part). I contacted GSK, obtained the following information: Inadvertent use of Kinrix in children younger then 4 years, immunogenicity & safety. I then phoned mother of child, informed her of the error and common side effects, agitation and irritabiity. She reported the patient had experienced these. I notified her that the doses were valid and would not need to be repeated and to call for further concerns. Today, she reports the patient is fine, doing well and had no further adverse side effects.
None
None
Lansoprazole
NKDA
None